The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...
N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...